| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Immunology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Immunology | ||
Phase 1/2 data readout example | Phase 1/2 | — | Subscribe to access the data. | Cell Therapies | Immunology |
Recent Updates
Recently added Catalysts
Kyverna Therapeutics, Inc.$7.77
-0.71 (-8.43%)
B 60Pipeline Score Undervalued Biotech · Commercial
Market Cap
527.09 M
EPS
-3.28
P/E Ratio
-
Value Trade
6.40 M
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
30.07 M
Operating CF
-41.60 M
Total Assets
257.02 M
Total Liabilities
61.44 M
Equity
195.58 M
D/E Ratio
12,345
-19.12 %
Week
-21.75 %
1 Month
8.38 %
3 Month
17.32 %
6 Month
-74.69 %
5 Year
-74.69 %
All Time
Cash Data
Cash Position
236.45 M
Monthly Burn
13.87 M
Runway
15.1 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
1.96 M
52 Week Range
2.43 - 13.67
% held by Insiders
38.03 %
% held by Institutions
42.89 %
Enterprise Value
324.40 M
Total Shares
60.80 M
Short %
19.16 %
Float Shares
36.78 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kyverna Therapeutics, Inc.
149Total events
8Upcoming
31Tier-1 (high impact)
2023 – 2026Coverage
Upcoming catalysts 2
TBD
T1BLA Submission
Subscribe to view catalyst details
TBD
T2Product Launch
Subscribe to view catalyst details
Event history 2
TBD
▲Management ChangeCorporate
Subscribe to view catalyst details
TBD
●BLA SubmissionKYV-101FiledRegulatory Filing
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | KYV-101 | BLA Submission | BLA | — | – | – | – |
2026-06-30 | KYV-101 | BLA Submission | BLA | — | – | – | – |
2026-06-30 | KYV-101 | BLA Submission | BLA | — | – | – | – |
Drug Pipeline Intelligence
B60
Pipeline Score $1.1B
Pipeline ValueUndervalued
Valuation Signal4
Drugs Scored6.7x
rNPV / MCap Top 87%
Micro Cap (rank 120 of 912)
Percentile RankKyverna Therapeutics, Inc. holds a solid B-grade pipeline (60/100), with $4.5B risk-adjusted pipeline value, led by KYV-101 anti-CD19 CAR-T cell therapy in Multiple Sclerosis (Phase 1), across $100B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KYV-101 anti-CD19 CAR-T cell therapy Monoclonal antibody | Multiple Sclerosis | Phase 1 | NCT06138132 | 45% | $1.9B | RECRUITING | 12 | - | - | Jun 1, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
miv-cel | stiff person syndrome | Phase 2 | 2026-04-22 | statistically significant improvements in mobility; all participants to discontinue chronic immunotherapies; majority of patients regaining function; single dose of 1 108 miv-cel CAR T cells; median follow-up of 6.5 months after miv-cel infusion (range, 4.4-12.2 months) Read More | need for any immunotherapies for SPS, to become the first and only approved treatment for SPS, to transform care or fundamentally change the treatment paradigm for SPS patients and caregivers or for other B-cell-driven a Read More | |
miv-cel | stiff person syndrome | Phase 2 | 2026-04-22 | statistically significant improvements in mobility; all participants to discontinue chronic immunotherapies; majority of patients regaining function; single dose of 1 108 miv-cel CAR T cells; median follow-up of 6.5 months after miv-cel infusion (range, 4.4-12.2 months) Read More | need for any immunotherapies for SPS, to become the first and only approved treatment for SPS, to transform care or fundamentally change the treatment paradigm for SPS patients and caregivers or for other B-cell-driven a Read More | |
miv-cel | stiff person syndrome | Phase 2 | 2026-04-22 | statistically significant improvements in mobility; all participants to discontinue chronic immunotherapies; majority of patients regaining function; single dose of 1 108 miv-cel CAR T cells; median follow-up of 6.5 months after miv-cel infusion (range, 4.4-12.2 months) Read More | need for any immunotherapies for SPS, to become the first and only approved treatment for SPS, to transform care or fundamentally change the treatment paradigm for SPS patients and caregivers or for other B-cell-driven a Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KYTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KYTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KYTXKyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Kyverna Therapeutics has appointed Ritesh Srivastava as Chief Legal and Compliance Officer to support its transition to a commercial-stage organization. Mr. Srivastava's extensive experience in legal and compliance will be crucial as Kyverna advances its CAR T-cell therapy, miv-cel, towards potential approval for stiff person syndrome. This appointment is part of Kyverna's strategic growth as it prepares for commercialization.
Read more →KYTXKyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Read more →KYTX▼ -10%on this news
are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as
Kyverna Therapeutics has appointed Greg Martini as Chief Financial Officer, effective May 18, 2026, succeeding Dr. Marc Grasso. Martini brings substantial financial leadership experience, previously serving as CFO at Ironwood Pharmaceuticals. He will oversee Kyverna's financial strategy as it advances its lead product, miv-cel, toward potential approval and commercialization, particularly focusing on autoimmune diseases. This transition is seen as critical for the company's growth and long-term success in the biopharmaceutical field.
Read more →KYTX▼ -10%on this news
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Read more →KYTXKyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics, a late-stage biopharmaceutical company, will present at two upcoming investor conferences: the H.C. Wainwright 4th Annual Nasdaq BioConnect Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026. The presentations will include discussions on their innovative cell therapies targeting autoimmune diseases, particularly their lead candidate, miv-cel.
Read more →KYTX▲ +5.4%on this news· ran to -17% by day 3shared move
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Kyverna Therapeutics has initiated a rolling BLA submission for its CAR T therapy, miv-cel, targeting stiff person syndrome (SPS), following a positive pre-BLA meeting with the FDA. The company reported strong financial results for Q1 2026 and is advancing its Phase 3 trial in generalized myasthenia gravis. The CEO emphasized the significance of this milestone for the company and the field of autoimmune therapies.
Read more →KYTXKyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Kyverna Therapeutics has appointed Nadia Dac as Chief Commercial Officer, effective May 4, 2026. With extensive experience in the biopharmaceutical industry, she will lead the commercial strategy for miv-cel, a potential first treatment for stiff person syndrome. Dac's background includes significant roles at Omeros and AbbVie, enhancing Kyverna's leadership in neuroimmunology.
Read more →KYTXstatements in this press release include, without limitation, those related to: Kyverna's next phase of growth, including its potential transition to a commercial-stage company; the potential launch of miv-cel in stiff p
Kyverna Therapeutics has appointed Nadia Dac as Chief Commercial Officer to spearhead the commercial strategy for miv-cel, a promising CAR T-cell therapy for stiff person syndrome. With over 30 years of experience in the biopharmaceutical space, Dac's leadership is anticipated to strengthen Kyverna's transition to a commercial-stage organization. Miv-cel has the potential to be the first approved treatment for its indication and aims to expand into other neuroimmunology diseases, propelling Kyverna's multi-indication franchise. The company is leveraging its advancing clinical data to support the launch and drive long-term growth.
Read more →KYTX▲ +5.4%on this news
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks 100% of patients achieved rapid, sustained improvements across MG-ADL
Kyverna Therapeutics presented longer-term Phase 2 data for miv-cel in generalized myasthenia gravis (gMG) at the AAN Annual Meeting. The updated data demonstrated that 100% of patients achieved sustained improvements across key clinical measures over 52 weeks, reinforcing confidence in the effectiveness of miv-cel's treatment. The well-tolerated profile further enhances its potential as a leading therapy in the field. Kyverna is currently progressing into a Phase 3 trial to further evaluate miv-cel's efficacy.
Read more →KYTX▲ +5.4%on this news
need for any immunotherapies for SPS, to become the first and only approved treatment for SPS, to transform care or fundamentally change the treatment paradigm for SPS patients and caregivers or for other B-cell-driven a
Kyverna Therapeutics announced promising results from its registrational trial of miv-cel for stiff person syndrome (SPS), presented at the AAN Annual Meeting. The single-dose therapy achieved strong, statistically significant improvements in mobility and allowed all participants to discontinue chronic immunotherapies. Miv-cel's performance across primary and secondary endpoints highlights its potential as the first approved treatment for SPS, which could transform care for patients suffering from this debilitating condition. The company is preparing to submit a Biologics License Application (BLA) for miv-cel's initial indication.
Read more →KYTX▲ +5.4%on this news
Highlighting New Data from Our Neuroimmunology Franchise at AAN
Kyverna Therapeutics presented new data regarding its neuroimmunology franchise at the AAN conference, focusing on the autoimmune CAR T therapy miv-cel for Stiff Person Syndrome (SPS) and generalized myasthenia gravis (gMG). The presentation highlighted promising results from ongoing clinical trials, indicating a high percentage of patients experiencing clinically meaningful benefits without the need for chronic immunotherapies. The company is currently preparing for a Biologics License Application (BLA) submission, driven by the positive data that underscores miv-cel's potential as a first-in-class therapy addressing significant unmet medical needs in the autoimmune space.
Read more →KYTX▼ -13.7%on this newsshared move
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Read more →KYTX▲ +13.3%on this newsshared move
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Read more →KYTXKyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics will host a conference call on April 22, 2026, to discuss data from its KYSA-8 trial of miv-cel in stiff person syndrome and longer-term data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis. These findings will be presented at the AAN Annual Meeting in Chicago. Miv-cel is a promising CAR T-cell therapy aimed at treating autoimmune diseases.
Read more →KYTXKyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Kyverna Therapeutics has reported its fourth quarter and full year 2025 financial results, highlighting advancements in its CAR T therapies for autoimmune diseases. The company is preparing for a BLA submission for its first CAR T treatment targeting stiff person syndrome, with a Phase 3 trial for generalized myasthenia gravis also in progress. Despite a strong cash position, the company reported increased net losses compared to the previous year.
Read more →KYTX▼ -5.4%on this news
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Read more →KYTX▼ -5.8%on this newsshared move
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Kyverna Therapeutics, a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences in March 2026. The events include the Leerink Partners Global Healthcare Conference and the Jefferies Biotech on the Beach Summit. The company aims to showcase its advancements in cell therapies for autoimmune diseases, particularly its lead CAR T-cell therapy candidate.
Read more →KYTXKyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Kyverna Therapeutics has appointed Sravan Emany and Andrew Miller to its Board of Directors, enhancing its leadership team. Emany, with extensive experience in capital markets and rare diseases, will chair the Audit Committee. Miller brings a strong background in clinical development and product approval, supporting Kyverna's growth in autoimmune CAR T therapies.
Read more →KYTXadvisor to Google Ventures, General Atlantic, Vida Ventures, Longwood Fund and the One Mind Foundation. He holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Chemical Engin
Kyverna Therapeutics has appointed Sravan Emany and Dr. Andrew Miller to its Board of Directors to support its next phase of growth. Emany brings extensive financial experience, while Miller contributes significant expertise in research and development. Both directors are expected to aid in the advancement of Kyverna's innovative cell therapies for autoimmune diseases, including ongoing trials for various conditions. The company's leadership maintains optimism about its prospects for long-term success and value creation.
Read more →KYTXKyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
Kyverna Therapeutics has appointed Mayo Pujols as Chief Technology Officer, effective February 9, 2026. Pujols brings over 30 years of experience in technical operations and will lead the company's transition to a commercial-stage entity. He succeeds Karen Walker, who will assist during the transition. The company is preparing for the potential launch of its CAR T-cell therapy, miv-cel, for stiff person syndrome.
Read more →KYTXpossibility that the past track records of Kyverna and its personnel may not be repeated or indicative of future success; and other factors discussed in the “Risk Factors” section of Kyverna's most recent A
Kyverna Therapeutics has appointed Mayo Pujols as the new Chief Technology Officer, effective February 9, 2026. Pujols, who has over 30 years of experience, succeeds Karen Walker, who will assist in the transition. The company is preparing for the potential launch of miv-cel for stiff person syndrome and aims to accelerate its operations in the field of CAR T-cell therapies for autoimmune diseases. Despite optimistic progress, there are noted uncertainties regarding the company's future success based on past performance.
Read more →KYTXKyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark r
Kyverna Therapeutics has provided a corporate update at the J.P. Morgan Healthcare Conference, outlining strategic priorities for 2026. The company announced plans for a Biologics License Application submission for its CAR T-cell therapy miv-cel for stiff person syndrome, anticipated by the first half of 2026. Additionally, they have successfully enrolled the first patient in a Phase 3 trial for generalized myasthenia gravis. Kyverna's recent follow-on offering extends their financial resources through 2028, enabling ongoing clinical developments and commercialization efforts.
Read more →KYTX▼ -7.3%on this news
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
Kyverna Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference on January 14, 2026. CEO Warner Biddle will discuss the company's advancements in cell therapies for autoimmune diseases. Kyverna's lead candidate, miv-cel, aims to transform treatment for B-cell-driven autoimmune conditions. A live webcast will be available for investors.
Read more →KYTXKyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
Kyverna Therapeutics has announced a public offering of 13,333,333 shares at $7.50 each, aiming to raise approximately $100 million. The offering is set to close around December 18, 2025, pending customary conditions. The company is focused on developing cell therapies for autoimmune diseases and has granted underwriters an option for additional shares.
Read more →KYTX▲ +23.2%on this newsshared move
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
Read more →KYTX▲ +23.2%on this newsshared move
Topline Data: KYSA-8 Registrational Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (SPS)
Kyverna Therapeutics' Miv-cel has reported promising topline results from its registrational trial, indicating a potential breakthrough in treating Stiff Person Syndrome (SPS). The therapy demonstrated statistically significant clinical benefits across primary and secondary endpoints, positioning it as a candidate for the first FDA-approved treatment in this area. The company anticipates submitting a Business License Application in the first half of 2026, highlighting the therapeutic's potential impact and the substantial unmet medical need within SPS. These developments underscore Kyverna's leadership in autoimmune CAR T therapies.
Read more →KYTX▲ +23.2%on this newsshared move
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-c
Kyverna Therapeutics has reported positive topline data from its KYSA-8 trial for mivocabtagene autoleucel (miv-cel), a CAR T-cell therapy targeting Stiff Person Syndrome (SPS). The study showed statistically significant improvements across all primary and secondary endpoints, indicating the potential for miv-cel to become the first FDA-approved therapy for SPS. The therapy was found to be well-tolerated, with no high-grade complications reported. Kyverna plans to submit a Biologics License Application (BLA) in the first half of 2026.
Read more →KYTXKyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results Topline data from registrational trial in stiff person syndrome (SPS) now expected in early 2026; narrowed from previous guid
Kyverna Therapeutics announced a business update and financial results for Q3 2025, reporting that topline data from its registrational trial in stiff person syndrome is now expected in early 2026. The company also presented positive interim data from its Phase 2 trial for generalized myasthenia gravis, achieving all primary and secondary endpoints. Additionally, Kyverna secured a $150 million loan facility to enhance its financial flexibility in advancing late-stage indications. However, it reported a net loss of $36.8 million for the quarter, raising concerns about its financial sustainability.
Read more →KYTXKyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance Initial funding of $25 million from the first of four tranches Facility strengthens Kyverna's financial flexibility, further s
Kyverna Therapeutics has secured a non-dilutive financing agreement with Oxford Finance for up to $150 million, with an initial $25 million funding. This financing will enhance Kyverna's financial flexibility, particularly in advancing its late-stage clinical programs in generalized myasthenia gravis and stiff person syndrome. The company anticipates initiating enrollment for its Phase 3 trial in the myasthenia gravis indication by the end of 2025. The topline data from the registrational Phase 2 trial for stiff person syndrome is expected in early 2026, showcasing significant progress in their clinical development pipeline.
Read more →KYTX▼ -5.8%on this newsshared move
This presentation contains forward-looking statements that are based on management's beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. ("Kyverna", "we", "our," or the
Kyverna Therapeutics presented interim data on KYV-101 from its Phase 2 clinical trial focusing on generalized myasthenia gravis (gMG). The results highlighted the potential of KYV-101 to achieve minimal symptom expression in patients while maintaining a manageable safety profile. The company's approach targets disease sources effectively, suggesting a compelling shift in treatment methods for gMG. No high-grade adverse effects have been observed in the initial patient cohort, lending further support to the therapy's viability.
Read more →KYTX▼ -5.8%on this newsshared move
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 Compelling results set new clinical standard in generalized myasthenia gravis (gMG)
Kyverna Therapeutics has announced promising interim results from the Phase 2 KYSA-6 trial of KYV-101 for treating generalized myasthenia gravis (gMG). All treated patients achieved significant improvements in the study's primary endpoints, demonstrating both efficacy and safety, with no serious adverse effects reported. These results strengthen confidence in advancing the KYSA-6 Phase 3 trial, aiming to establish a new standard of care in gMG management. The company plans to initiate Phase 3 trial enrollment by the end of the year.
Read more →KYTXKyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Read more →KYTXKyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event
Read more →KYTXKyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H
Kyverna Therapeutics has provided a business update and reported its financial results for the second quarter of 2025. The company announced that it anticipates topline data for its Phase 2 trial of KYV-101 in stiff person syndrome by the first half of 2026, while also preparing to start a registrational Phase 3 trial in myasthenia gravis with enrollment expected by year-end 2025. Kyverna has a strong cash position of $211.7 million, ensuring support for upcoming clinical milestones despite reporting a net loss of $42.1 million for the quarter.
Read more →KYTX▼ -16.1%on this news
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
Kyverna Therapeutics will host a virtual event on August 28, 2025, featuring Key Opinion Leaders discussing its neuroimmunology franchise, particularly the KYV-101 therapy. The event aims to provide insights into the company's strategy and ongoing clinical trials for autoimmune diseases. A Q&A session will follow the presentations, allowing for direct engagement with the management team.
Read more →KYTX▼ -5.7%on this news
Kyverna Therapeutics Announces Appointment of New Chief Financial Officer
Kyverna Therapeutics has appointed Dr. Marc Grasso as its new Chief Financial Officer, effective immediately. Dr. Grasso brings over 25 years of experience in public companies and capital markets, succeeding Ryan Jones, who will transition to a strategic advisor role. His expertise is expected to support Kyverna's growth and development of CAR T-cell therapies for autoimmune diseases.
Read more →KYTXKyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
Kyverna Therapeutics will present at the Jefferies Global Healthcare Conference on June 4, 2025. CEO Warner Biddle will discuss the company's advancements in cell therapies for autoimmune diseases. The presentation will be accessible via a live webcast, with a replay available for 30 days. Kyverna's lead candidate, KYV-101, is in late-stage clinical development.
Read more →KYTX▼ -7.3%on this news
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
Kyverna Therapeutics has completed enrollment in its Phase 2 trial for stiff person syndrome (SPS) and is on track for topline data in the first half of 2026. The company is also advancing to a Phase 3 trial for myasthenia gravis (MG) after a successful FDA meeting. Despite a net loss of $44.6 million in Q1 2025, Kyverna maintains a strong financial position with a cash runway into 2027.
Read more →KYTX▼ -15.1%on this news
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Kyverna Therapeutics reported its business update and financial results for 2024, highlighting progress in its clinical trials for KYV-101, particularly in stiff person syndrome. The company has aligned with the FDA for a registrational Phase 2 trial and anticipates topline data in 2026. Despite a significant net loss, the company maintains a strong cash position to support its ongoing clinical development.
Read more →KYTXKyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Kyverna Therapeutics will present at the Leerink Partners Global Biopharma Conference on March 10, 2025. CEO Warner Biddle will discuss the company's progress in developing cell therapies for autoimmune diseases. Kyverna's lead candidate, KYV-101, is undergoing Phase 2 trials for stiff person syndrome and myasthenia gravis, among other indications.
Read more →KYTXKyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
Kyverna Therapeutics has appointed Dr. Naji Gehchan as Chief Medical and Development Officer. With over 20 years of experience in clinical development and a strong background in immunology, Dr. Gehchan is expected to lead the company's research and clinical development efforts. His appointment comes as Kyverna prepares for the late-stage development of its lead candidate, KYV-101.
Read more →KYTXKyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference
Kyverna Therapeutics is set to present its strategic priorities at the 43rd Annual J.P. Morgan Healthcare Conference. The company aims to advance its lead CAR T therapy, KYV-101, for stiff person syndrome, with a pivotal Phase 2 trial already enrolling patients. Additionally, KYV-102 is expected to enhance patient access through rapid manufacturing. With a cash runway extending into 2027, Kyverna is focused on late-stage development and commercialization of its therapies.
Read more →KYTX▼ -7.1%on this news
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference
Read more →KYTXKyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth
Kyverna Therapeutics has announced key leadership appointments, including Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior VP of Corporate Affairs. These appointments aim to strengthen the company's capabilities as it advances its clinical-stage cell therapies for autoimmune diseases. The new leaders bring extensive experience from notable biotech firms, positioning Kyverna for its next growth phase.
Read more →KYTX▼ -5.1%on this news· ran to -19% by day 3
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Read more →KYTXKyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise i
Kyverna Therapeutics has announced significant updates alongside its third quarter 2024 financial results. Warner Biddle has been appointed CEO, leading progress in the company's KYV-101 clinical development for autoimmune diseases. The company reported a solid cash position of $321.6 million despite a quarterly net loss of $34.3 million. Clinical data presented at ECTRIMS and upcoming at ACR Convergence suggest KYV-101's promising potential in treating several conditions, including lupus nephritis and multiple sclerosis. Kyverna continues its efforts to enhance its leadership team and manufacturing capabilities.
Read more →KYTX▼ -7.8%on this news
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth
Kyverna Therapeutics has appointed Mert Aktar to its Board of Directors, enhancing the board's expertise in corporate strategy and business development. Aktar, who has over 20 years of biopharmaceutical experience, will lend his knowledge particularly in cell therapy as Kyverna continues to develop its lead candidate, KYV-101. This appointment comes at a pivotal time for the company as it advances through various clinical trials targeting autoimmune diseases. Kyverna aims to leverage Aktar's background to improve their strategic direction and growth.
Read more →KYTX▼ -7.8%on this news
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients...
Kyverna Therapeutics has appointed Mert Aktar to its Board of Directors, enhancing its leadership with his extensive experience in biopharmaceuticals and cell therapy. Aktar's background includes significant roles at Kite Pharma and Shire, where he contributed to corporate development and strategy. His expertise is expected to support Kyverna's ongoing clinical trials and growth in the CAR T-cell therapy market.
Read more →KYTXKyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Read more →KYTXKyverna Therapeutics Announces Leadership Update - Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience,
Kyverna Therapeutics has appointed Warner Biddle as its new Chief Executive Officer, succeeding Peter Maag, who resigned. Biddle brings over 30 years of experience in the pharmaceutical sector, particularly in cell therapies, and is expected to guide the company through its next phase of growth. Christi Shaw joins the Board of Directors, adding further expertise to Kyverna's leadership. The company is advancing its promising CAR T-cell therapy KYV-101 into later stages of development, seeking to capitalize on commercial opportunities in autoimmune diseases.
Read more →KYTXKyverna Therapeutics Announces Leadership Update
Kyverna Therapeutics Announces Leadership Update
Read more →KYTX▲ +13.4%on this news
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Read more →KYTXKyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...
Kyverna Therapeutics reported a positive business update for Q2 2024, highlighting the ongoing clinical trials for KYV-101 in neurology and rheumatology. The company received FDA RMAT Designations for treating Stiff-Person Syndrome and Myasthenia Gravis, showcasing promising safety and efficacy results. However, the financial report indicates a significant net loss compared to the previous year.
Read more →KYTXKyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results • Actively recruiting clinical trials in neurology and rheumatology with KYV-101 • No severe ICANS or CRS repo
Kyverna Therapeutics has reported a business update along with second quarter 2024 financial results, highlighting advancements for its lead product candidate, KYV-101. The company actively recruits for clinical trials in neurology and rheumatology, underscoring key FDA designations for autoimmune disorders. Importantly, there have been no severe adverse effects reported in patients treated with KYV-101, and one patient has achieved disease-free status after a year. However, Kyverna's financial losses have increased, raising concerns about the sustainability of its clinical programs.
Read more →KYTXKyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
Read more →KYTXKyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients...
Kyverna Therapeutics has announced that its CAR T-cell therapy, KYV-101, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating refractory stiff-person syndrome. This designation will facilitate expert guidance from the FDA, potentially accelerating the development of this innovative treatment. Initial clinical outcomes have shown promise, raising hopes for improved patient outcomes.
Read more →KYTXKyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome The application was evaluated based on the positive clinical outcomes of KYV-101 in pati
Kyverna Therapeutics has announced that its KYV-101 therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for treating refractory Stiff-Person Syndrome. This designation aims to expedite the development and review process of promising therapies. The positive clinical outcomes observed during previous treatments conducted in Germany were a basis for the FDA's evaluation. KYV-101 is designed to provide effective treatment options for patients suffering from this rare and debilitating autoimmune condition.
Read more →KYTX▲ +7.9%on this news
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Read more →KYTX▼ -17.2%on this newsshared move
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Read more →KYTX▼ -34%on this news· ran to -45% by day 1shared move
Time Session Title Presenter 8:15-8:20 Welcome and Introduction Peter Maag, PhD Kyverna Therapeutics 8:20-8:35 Long-Term Clinical Experience and Mechanistic Insights Gerhard Kr nke, MD Charit – University Medicine
Kyverna Therapeutics presented updates on its anti-CD19 CAR T-cell therapy, KYV-101, highlighting its application in rheumatologic autoimmune diseases. The session included discussions on long-term clinical experiences and the advancement of CAR T trials, emphasizing the ability to treat a range of indications effectively. Initial data indicate encouraging outcomes among treated patients. The presentation also covered the company's dedication to generating clinical insights and their commitment to addressing unmet treatment needs.
Read more →KYTXKyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Read more →KYTXKyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024
Read more →KYTX▲ +5.9%on this news
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...
Kyverna Therapeutics has reported its first quarter 2024 financial results, highlighting advancements in the clinical development of its lead CAR T-cell therapy, KYV-101, for autoimmune diseases. The company treated 30 patients across various conditions and received Orphan Drug Designation for myasthenia gravis. Despite a net loss of $26.7 million, Kyverna's financial position remains strong with substantial cash reserves following a recent public offering.
Read more →KYTX▲ +5.9%on this news
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology • Treated
Kyverna Therapeutics has reported its financial results for Q1 2024, highlighting advances in its clinical trials targeting autoimmune diseases in rheumatology and neurology. The company has treated 30 patients with its lead product candidate, KYV-101, which has received Orphan Drug Designation from the FDA. Despite a substantial net loss of $26.7 million during the quarter, Kyverna's balance sheet remains strong due to recent funding. Additionally, the company is progressing in various Phase 1/2 clinical trials and anticipates future interim data releases.
Read more →KYTXKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
Read more →KYTX▼ -9.3%on this news
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
Read more →KYTX▲ +7%on this newsshared move
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for...
Kyverna Therapeutics reported significant advancements in its clinical development for KYV-101, a CAR T-cell therapy targeting autoimmune diseases. The company achieved FDA clearance for multiple Phase 2 trials and strengthened its financial position with a recent IPO. However, it also reported a substantial net loss for the year 2023, reflecting ongoing operational costs.
Read more →KYTX▲ +7%on this newsshared move
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results • Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology • Strong balan
Kyverna Therapeutics reported its full year 2023 financial results, highlighting significant advancements in the clinical development of its lead candidate, KYV-101, targeting autoimmune diseases. The company noted a boost to its finances from an initial public offering, expected to fund operations into 2026. Despite a marked increase in net losses, Kyverna received FDA Fast Track Designations for multiple sclerosis and myasthenia gravis, validating its ongoing trials and developments. The company continues to innovate with its Ingenui-T manufacturing process and aims to make further regulatory progress in the upcoming year.
Read more →KYTXKyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
Read more →KYTXKyverna Therapeutics Congratulates Prof. G. Schett et al. on the Publication of a Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy
Kyverna Therapeutics Congratulates Prof. G. Schett et al. on the Publication of a Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy
Read more →KYTXKyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Read more →KYTXKyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
Read more →KYTXKyverna Therapeutics announces first publication of Ingenui-T, a novel CAR T-cell vein-to-vein manufacturing process
Kyverna Therapeutics announces first publication of Ingenui-T, a novel CAR T-cell vein-to-vein manufacturing process
Read more →KYTXKyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Read more →KYTXKyverna's KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial
Kyverna's KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial
Read more →KYTXKyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Read more →KYTXKyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101
Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101
Read more →KYTXKyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101, a Fully Human CD19 CAR T-Cell Therapy to Treat Myasthenia Gravis
Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101, a Fully Human CD19 CAR T-Cell Therapy to Treat Myasthenia Gravis
Read more →KYTXKyverna Therapeutics Congratulates the Teams at the Universities of Bochum and Magdeburg for a Late Breaker Case Report in a Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101
Kyverna Therapeutics Congratulates the Teams at the Universities of Bochum and Magdeburg for a Late Breaker Case Report in a Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101
Read more →KYTXKyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on Receiving the 2023 ACR Distinguished Clinical Investigator Award
Kyverna Therapeutics Congratulates Scientific Advisory Board Member Peter A. Merkel, M.D., M.P.H. on Receiving the 2023 ACR Distinguished Clinical Investigator Award
Read more →KYTXKyverna Therapeutics Hosts a CAR T-Cell Therapy Symposium in Berlin to Discuss Investigational Treatment Options in Severe Neurological Autoimmune Diseases
Kyverna Therapeutics Hosts a CAR T-Cell Therapy Symposium in Berlin to Discuss Investigational Treatment Options in Severe Neurological Autoimmune Diseases
Read more →KYTXKyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases
Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases
Read more →KYTXKyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma
Read more →KYTXKyverna Therapeutics and ElevateBio to Advance Kyverna's Ingenui-T Cell Therapy Manufacturing
Kyverna Therapeutics and ElevateBio to Advance Kyverna's Ingenui-T Cell Therapy Manufacturing
Read more →KYTXKyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
Read more →KYTXKyverna Therapeutics Announces Achievement of 28-Day Post-Infusion Milestone for First U.S. Patient Dosed in Phase 1 Clinical Trial of CD19 CAR T-Cell Therapy for Lupus Nephritis
Kyverna Therapeutics Announces Achievement of 28-Day Post-Infusion Milestone for First U.S. Patient Dosed in Phase 1 Clinical Trial of CD19 CAR T-Cell Therapy for Lupus Nephritis
Read more →KYTXKyverna Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Kyverna Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Read more →KYTXVerily and Kyverna Therapeutics Announce Collaboration to Advance Cell Therapy for Autoimmune Diseases
Verily and Kyverna Therapeutics Announce Collaboration to Advance Cell Therapy for Autoimmune Diseases
Read more →KYTXKyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Read more →KYTXKyverna Therapeutics Announces Regulatory Approval of Phase 1/2 Clinical Trial for KYV-101 in Germany
Kyverna Therapeutics Announces Regulatory Approval of Phase 1/2 Clinical Trial for KYV-101 in Germany
Read more →KYTXKyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.
Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S.
Read more →KYTXKyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis
Read more →KYTXKyverna Therapeutics to Present New Data of KYV-101 in Lupus at European Congress of Rheumatology
Kyverna Therapeutics to Present New Data of KYV-101 in Lupus at European Congress of Rheumatology
Read more →KYTXKyverna Therapeutics to Present New Data of KYV-101 in Lupus at American Society of Gene & Cell Therapy 26th Annual Meeting
Kyverna Therapeutics to Present New Data of KYV-101 in Lupus at American Society of Gene & Cell Therapy 26th Annual Meeting
Read more →KYTXKyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis
Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Lupus Nephritis
Read more →KYTXKyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis
Read more →KYTXKyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer
Read more →KYTXKyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board
Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board
Read more →KYTXKyverna Therapeutics Names Cell Therapy Expert Tom Van Blarcom, Ph.D., as Senior Vice President, Head of Research
Kyverna Therapeutics Names Cell Therapy Expert Tom Van Blarcom, Ph.D., as Senior Vice President, Head of Research
Read more →KYTXKyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Read more →KYTXKyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Read more →KYTXKyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer
Kyverna Therapeutics Announces the Appointment of James Chung, M.D., Ph.D., as Chief Medical Officer
Read more →KYTXKyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Read more →Competitive Position
How KYTX ranks across every disease it competes inCompetitive Position is a premium feature
See how KYTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial